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ABSTRACT 
Heart failure (HF) and type 2 diabetes mellitus (T2DM) are both growing public health 
concerns contributing to major medical and economic burdens to society. T2DM increases 
the risk of HF, frequently occurs concomitantly with HF, and worsens the prognosis of HF. 
Several anti-hyperglycemic medications have been associated with a concern for worse HF 
outcomes. More recently, the results of the EMPAREG OUTCOME trial showed that the 
sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin was associated with a 
pronounced and precocious 32% reduction in cardiovascular mortality in subjects with T2DM 
and established cardiovascular disease. These benefits were more related to a reduction in 
incident HF events rather than to ischemic vascular endpoints. Several mechanisms have 
been put forward to explain these benefits, which also raise the possibility of using these 
drugs as therapies not only in the prevention of HF, but also for the treatment of patients 
with established heart failure regardless of the presence or absence of diabetes.  Several 
large trials are currently exploring this postulate.   
 
 
Keywords: diabetes mellitus; heart failure; SGLT-2 inhibitor; empagliflozin  
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Heart failure (HF) is a global health problem with a prevalence of ~26 million worldwide. 
Patients with HF are at a 40%-50% risk of mortality within five years of diagnosis,1 and suffer 
from recurrent hospitalizations and poor quality of life. Type 2 diabetes mellitus (T2DM) is 
growing with a prevalence of over 400 million globally.2 The deleterious effects of T2DM can 
be separated into microvascular (neuropathy, nephropathy, retinopathy) and macrovascular 
(coronary disease, stroke, peripheral arterial disease) complications. While there is 
moderate to high quality evidence that glucose control reduces the risk of microvascular 
complications, its beneficial effect on macrovascular complications are less apparent and 
appear to take longer to manifest.3 Cardiovascular diseases (CVD) account for approximately 
half of the deaths in T2DM.4 CVD, HF, and T2DM are all associated with chronic kidney 
disease (CKD), which together further worsen prognosis.5, 6 
There is now an increased recognition of the association between HF and T2DM,7 
with increasing prevalence of patients with both diseases concomitantly. The patients with a 
concomitant disease have a worse prognosis compared to those with either disease alone. 
HF is more than twice as likely to develop in patients with T2DM and may develop 
independent of coronary disease.8 Conversely, HF is associated with insulin resistance and a 
higher risk for developing T2DM.9 The prevalence of T2DM among patients with HF is as high 
as 40-45%10 and the prevalence of HF in patients with T2DM is reported to be 10-23%.11 Indeed, 
HF was the second most common initial CVD presentation in patients with T2DM, at 14.1%.12 
The results of the recently published EMPA-REG OUTCOME trial, with the sodium-
glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin hold promise for CV risk reduction in 
diabetes. Particularly intriguing are the potential benefit with regards to HF. The current 
review aims to examine the potential role of this class of drugs in patients with HF with and 
without DM. 
 
HEART FAILURE OUTCOMES IN DIABETES MELLITUS CLINICAL TRIALS  
In 2008, the US Food and Drug Administration (FDA) put forth guidelines for drug 
manufacturers to demonstrate that new anti-hyperglycemic medications should not 
increase the risk for CVD, with a focus on cardiovascular death, myocardial infarction, or 
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stroke.13 Until recently, there was no evidence for HF risk reduction; conversely there were 
some concerns of worsening HF risk with therapies targeting glucose control.14 For example, 
several trials showed an increased risk of HF with thiazolidinediones,15 16 thus these agents 
are not recommended in patients with HF.17 Interestingly, the dipeptidyl peptidase 4 
inhibitor (DPP4i) saxagliptin and alogliptin but not sitagliptin may increase the risk of HF.18 
Sulfonylureas have been associated with increased risk of developing HF, but most data 
were derived from observational studies and definitive prospective trials are needed.19, 20 
 
The EMPA-REG OUTCOME Trial 
The EMPA-REG OUTCOME trial was the first trial to show cardiovascular mortality 
reduction in high-risk patients with T2DM treated with empagliflozin, an SGLT2 inhibitor. This 
trial randomized 7020 patients with T2DM and CVD to 10mg or 25mg of empagliflozin daily or 
to placebo.21 The primary endpoint of death from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke was seen in 10.5% in the pooled empagliflozin group vs. 12.1% 
with placebo (hazard ratio [HR] 0.86; 95% confidence interval [CI], 0.74 to 0.99; P=0.04) in 
the 3.1 year follow up period. There were no significant differences in rates of myocardial 
infarction or stroke but there was a 38% lower risk of cardiovascular death and 32% risk 
reduction in all-cause death (both P<0.001) with empagliflozin.  
Empagliflozin overall reduced the risk for HF hospitalization by 35% and HF death or 
hospitalization by 39% (both P<0.001), with benefits seen in both patients with and without 
documented HF at baseline.22 The reduced adjudicated endpoint of HF hospitalization was 
supported by similar reductions of investigator reported HF, and the introduction of loop 
diuretics (as a surrogate for HF). The prevalence of manifest HF at baseline was 10% in the 
trial. HF ascertainment was based on self-reports without characterization of functional 
class, ejection fraction, or biomarker data. Detailed HF phenotyping, including 
echocardiography, was not performed in the EMPA-REG OUTCOME trial and it is unclear 
whether the HF-related benefits seen were limited to development of HFrEF or HFpEF. 
When compared with other hypertension,23-27 HFpEF28-32 and HFrEF33-35 trials, the mortality 
and HF hospitalization rates in the EMPA-REG OUTCOME trial are comparable to other high 
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risk population trials, and the event rates among those who had baseline HF were 
comparable to those observed in HFpEF trials. (Figure 1A and B) This may suggests 
unsuspected high prevalence of HF in this population at baseline. This also raises the 
possibility that among those with HF-associated endpoints in this study, there perhaps may 
be more patients with HFpEF compared to those with HFrEF. This is consistent with what 
prior epidemiological studies suggesting an increase in HFpEF in patients with T2DM. This 
work is also consistent with rising evidence of a link between obesity, renal disease and 
HFpEF.36  
 
DISSOCIATION BETWEEN GLUCOSE CONTROL AND HEART FAILURE OUTCOMES 
Interestingly, there was no significant relationship between glycemic control and HF 
outcomes in the EMPA-REG OUTCOME trial. Both the 10mg and 25mg doses had similar 
effects on outcomes. HbA1c level at randomization was not a determinant of benefit and 
patients across the spectrum of initial HbA1c values benefited from the treatment with 
empagliflozin. Similarly, HF patients who had a larger (≥0.3%) vs. a more modest (≤0.3%) 
reduction in HbA1c benefited equally from empagliflozin.37 These observations suggest that 
the benefit with this agent is not related entirely to glucose control per se and other 
mechanisms mediate its cardiovascular-protective effects. It is noteworthy that another 
class of drug, glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide and semaglutide, 
were effective in lowering HbA1C and significantly improved other cardiovascular outcomes 
but not HF events.38-40 However, when used in patients with stable chronic HF with or 
without DM, liraglutide was associated with higher cardiac adverse events.41 
 
MECHANISM OF ACTION OF SGLT2-INHIBITORS FOR GLUCOSE CONTROL 
SGLT2 is located almost exclusively in the kidney, while SGLT1 transporters are also located 
in the intestines, heart, and skeletal muscles.42 Glucose reabsorption in the kidneys occurs in 
a sodium-dependent manner via SGLT proteins, with most reabsorption occurring at the 
proximal convoluted tubule through SGLT2 and a smaller portion in the distal segment of 
the proximal tubule by SGLT1.43 Once the maximum glucose transport capacity has been 
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reached, excess glucose is excreted into the urine. SGLT2 inhibitors lead to increased urinary 
glucose excretion by blocking SGLT2-mediated glucose reabsorption. (Figure 2)  
 
POTENTIAL MECHANISM BENEFITING HEART FAILURE 
While the exact mechanism by which empagliflozin may impact HF outcomes is not 
understood, several effects of SGLT2 inhibitors can potentially be of benefit. Any potential 
mechanism of SGLT2 inhibitors benefiting HF should take into account the simultaneous 
reduction of CV mortality and the very rapid reduction of HF and cardiovascular mortality as 
well. (Figure 3, partially adapted from 44) 
 
Lowering Blood Pressure: Treatment with an SGLT2 inhibitor is associated with reduction in 
systolic and diastolic blood pressure. Unlike vasodilators, this change in blood pressure is 
not associated with an increase in heart rate45, suggesting that the sympathetic nervous 
system is not activated.46 Reduction in blood pressure is likely multifactorial related to 
natriuresis, reduced plasma volume, non-fluid weight loss, as well as direct vascular 
effects.47 
 
Sodium and Fluid Loss: SGLT2 inhibitors induce osmotic diuresis and natriuresis through the 
decreased reabsorption of glucose and sodium, 48 resulting in less extracellular volume, 
possible reduction of vascular wall stress, improving cardiac function and potentially 
reducing congestion. Reduction in plasma volume may also lead to reduced myocardial 
stretch and natriuretic peptide levels,44, 49 as well as improving symptom and functional 
capacity. Loop and thiazide diuretics work primarily by natriuresis, whereas vaptans mediate 
their effects via aquaresis. In contrast, SGLT2 inhibitors induce natriuresis as well as osmotic 
diuresis via glucosuria. The increase in sodium excretion is temporary,50 thus the mechanism 
might be an initial reduction of whole body sodium content. This then translates into a 
benefit via hemodynamic effects as well as an effect on sodium content within 
cardiomyocytes, i.e. an increase in sodium in these cells favors arrhythmias in HF models.51 In 
addition, compared with conventional osmotic diuretics, empagliflozin does not affect 
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plasma osmolality. While both SGLT2 inhibitors and thiazide-like diuretics work on the 
proximal tubule of the nephron, thiazides are associated with hypokalemia, increased serum 
uric acid, and impaired glucose tolerance while SGLT2 inhibitors are not associated with 
increased serum uric acid or impaired glucose tolerance and no changes in serum potassium 
levels occur.52 
Under physiologic concentrations of glucose, SGLT2-mediated glucose uptake 
stimulates the sodium-hydrogen exchanger (NHE)3, involved in the reabsorption of sodium 
bicarbonate, while supra-physiologic glucose levels inhibit NHE3, inducing natriuresis .53, 54 In 
a HF rat model, the up-regulation of NHE3 likely contribute to attenuation of the natriuresis 
and volume expansion.55 SGLT2 inhibitors result in decreased activity in NHE3, possibly 
contributing to natriuresis, and reduction in blood pressure.56 
 
Effects on the Renin Angiotensin System:  Under physiologic conditions, the majority of 
sodium is reabsorbed in the proximal tubule. This enables the macula densa, located at the 
transition between the ascending limb of the loop of Henle and the distal convoluted tubule 
to sense changes in sodium concentration and adjust glomerular filtration rate via 
tubuloglomerular feedback. The decrease in sodium delivery to the distal tubule leads to a 
compensatory increase in renin by the juxtaglomerular cells and activation of the 
downstream angiotensin system.48 In the setting of HF, decreased renal blood flow leads to 
sodium reabsorption via the proximal tubule, likely enhanced by SGLT2 augmented by 
activation of the sympathetic nervous system and angiotensin II.57, 58 While inhibition of 
SGLT2 may attenuate the downstream effects of neurohormonal activation in HF,59 other 
studies suggest that in response to volume contraction, the levels of aldosterone and 
angiotensin II, may actually increase in response to SGLT2 inhibition.42 
 
Weight Loss: Compared to some other anti-diabetic agents, SGLT2 inhibitors are associated 
with reduction in body weight.60 This occurs rapidly initially and then gradually until a 
plateau is reached and it is sustained over time. The initial decline is thought to occur as a 
result of osmotic diuresis; however the subsequent gradual and predominant weight 
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reduction is likely caused caloric urinary glucose loss resulting in reduction in visceral fat 
mass.61 There is ample evidence that obesity per se is a strong risk factor for incident HF but 
whether weight loss and the method of weight loss influence outcomes in patients with 
manifest HF,62 or those with diabetes,63 remains controversial.  
 
Maintenance of Kidney Function: Decline in renal function is accompanied by disruption in 
volume homeostasis and predisposition to progression of HF.64 More recently, renal 
dysfunction has been proposed as a potential causal risk factor for HFpEF.36 Albuminuria is 
an important marker of vascular resistance and progression of kidney disease.65 SGLT2 
inhibitors reduce urinary albumin excretion and potential preservation of glomerular 
filtration rate over time. Recently Wanner et al reported relevant data from EMPA-REG 
OUTCOME trial.66 New onset or worsening of nephropathy, a pre-specified exploratory 
composite renal endpoint, was reduced by 39%. Compared with placebo, empagliflozin 
significantly reduced the initiation of renal replacement therapy by 55%, doubling of serum 
creatinine by 44%, and new onset of macroalbuminuria by 38%. Empagliflozin also 
significantly slowed the decline in estimated glomerular filtration rate over time compared 
with placebo. It is important to note that these renal effects occurred on the background of 
renin-angiotensin-aldosterone system blockers for renal protection. 47, 66 The preservation of 
renal function by empagliflozin may contribute to its beneficial effects on HF. It should also 
be noted that while the GLP-1 receptor agonists also lessened albuminuria, their effects on 
other renal outcomes appear less clear.38, 39 In T2DM where there is increased glucose and 
sodium reabsorption via SGLT2, decreased sodium delivery at the distal tubule results in 
afferent arteriole vasodilation leading to an increase in glomerular filtration rate, which is 
also known as “hyperfiltration”. Chronic hyperfiltration contributes to nephron loss. The 
target of SGLT1 inhibitors (either for selective SGLT1 inhibitors or for combined SGLT1+SGLT2 
inhibitors) is the intestinal SGLT1.These SGLT1 inhibitor-compounds do not reach a 
concentration in the renal tubules that would allow for a renal inhibition of SGLT1. Therefore, 
for renal hemodynamics, the SGLT1 inhibition part is negligible regarding renal 
hemodynamics, for all currently available compounds. Regarding urinary glucose excretion 
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(UGE), this is relatively comparable between selective and non-selective SGLT inhibitors and 
both are associated with reduced UGE in patients with chronic kidney disease. 
 
Reduced Uric Acid and Oxidative Stress: Elevations in uric acid is associated with oxidative 
stress and increased reactive oxygen species, increase in numerous cytokines, activation of 
the renin angiotensin system, and hypertension.67, 68 SGLT2 inhibitors result in reduction in 
uric acid levels.69 In animal studies, empagliflozin reduced oxidative stress.70 Given the 
association of uric acid on both the renal and CV systems, this may be a mechanism for the 
impact of SGLT2 inhibitors on HF.  
 
Increased Hematocrit: SGLT 2 inhibitors also result in increased hemoglobin and hematocrit 
levels.71 Univariate analysis of potential mediators for empagliflozin's CV mortality benefit 
demonstrated that hematocrit showed a 52% change in the hazard ratio for CV mortality.72 
This may be related to hemoconcentration of plasma volume, as discussed above. SGLT2 
inhibitors ameliorate tubulointerstitial hypoxia through reduction in proximal tubule 
workload, though evidence for this theory is currently limited to animal models.73 This allows 
for stimulation of erythropoiesis, which may partially explain the observed increase in 
hematocrit. However, the increase in erythropoietin is transient while the change in 
hematocrit is sustained over time.74 Hemoglobin provides better tissue oxygenation and is 
regulated through hypoxia-inducible factor 1-alpha expression and subsequent 
erythropoietin secretion, factors influenced by SGLT2 inhibitors.75 
 
Decreased Inflammation: SGLT2 inhibitors have been shown to reduce biomarkers of 
inflammation in animal models.76 In a rat model, the anti-inflammatory effects may be 
mediated through inhibition of NADPH oxidase activity and decreased formation of 
advanced glycation end products.70 This may benefit both the sequelae of T2DM and HF 
such as vascular dysfunction and fibrosis.70  
 
 11 
Decreased Arterial Stiffness: Increased arterial stiffness is a predictor of HF events and death 
and is associated with hypertension, obesity, and worse HF.42 Empagliflozin has been shown 
to reduce arterial stiffness in patients with type I DM.46 This may be related to weight loss, 
improved arterial compliance and smooth muscle relaxation through a negative sodium 
balance,46 which may be of particular benefit in HFpEF. In patients with T2DM and 
hypertension, empagliflozin was associated with reductions in markers of arterial stiffness 
and vascular resistance.77 The reduction in arterial stiffness via SGLT2 inhibition, coupled 
with improved myocardial energetics and calcium handling could act together to improve 
HF.78 Improvement in myocardial energetics would likely mean that systolic wall stress is 
shifted earlier rather than later, which is what is seen in HF. Thus, myocardial-arterial 
coupling improves. At the same time, the cardiomyocytes are less vulnerable to stress 
because of improved calcium handling.  
 
Metabolism: SGLT2 inhibition increases glucagon levels.79 In addition to its role in glucose 
homeostasis, glucagon also acts as a stress hormone.80 Glucagon receptors expressed on 
cardiac myocytes facilitate its positive inotropic and chronotropic effects on the heart.81 In 
the setting of T2DM, the hyperglycemic state results in increased glucose uptake by cardiac 
myocytes beyond its oxidative capacity (glucotoxicity), impairing cardiac function.61 SGLT2 
inhibitors as well as metformin decrease excess glucose uptake by the heart, albeit through 
different mechanisms.61 Under normal circumstances, the heart is primarily fueled by fatty 
acids. In the setting of diabetes, the hyperglycemic state results in increased glucose uptake 
by cardiac myocytes, impairing cardiac function.61 The elevated level of beta 
hydroxybutyrate seen with SGLT2 inhibitors82 results in a shift in fuel supply from fatty acids 
and glucose, which are less energy efficient in the setting of T2DM, towards the more 
energy-efficient ketones. This in turn improves myocardial and renal metabolic efficiency 
while reducing oxygen consumption.83, 84 This ketone hypothesis, however, is currently 
under study.85 
  
POTENTIAL BENEFIT ACROSS THE SPECTRUM OF HEART FAILURE 
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The exact mechanisms by which empagliflozin lowers the risk of cardiovascular death in 
patients with T2DM and might influence HF outcomes are not clearly understood. Most of 
the pharmacodynamic effects of SGLT2 inhibitors have the potential to reduce the 
development and progression of both HFrEF and HFpEF.86 Thus, the potential for benefit 
with these agents should be properly tested across the left ventricular ejection fraction 
spectrum in patients with HF in carefully designed, randomized controlled trials with 
sufficient statistical power.  Importantly, since the HF benefit of SGLT2 inhibitors does not 
seem to be related to glucose control and these agents are associated with low rates of 
hypoglycemia in states of normal glucose concentration, it is rational to postulate that 
SGLT2 inhibitors might be both safe and effective in HF patients without DM as well. In fact, 
in a zebrafish HF model, empagliflozin was able to attenuate HF in the absence of 
hyperglycemia.87 
One unifying hypothesis is that the dominant mechanism of action of empagliflozin is 
a glucouretic effect without the usual adverse effects of conventional diuretics. In the 
EMPA-REG OUTCOME trial, the early, sizeable and persistent effect of empagliflozin in 
raising hematocrit and serum albumin, a drop in blood pressure, and a decrease in body 
weight may be interpreted as the effect on plasma volume and hemoconcentration, 
resulting from a benign “smart” or “diabetes-directed” diuretic effect. Indeed, this 
glucouretic effect is a striking variance with those observed with all other diuretics. The 
apparently adverse effects inherently associated with the pharmacology of the conventional 
loop diuretics and thiazides used in HF may counter and/or dampen their potential survival 
benefits. Still, other mechanism such as changes in cardiac metabolisms by SGLT2 inhibitor 
treatment may also contribute to beneficial effects in HF. In addition to clinical trials, further 
laboratory experimental data are warranted to further elucidate the underlying mechanisms 
of cardioprotection. 
 
CLASS EFFECT OF SGLT2 INHIBITORS 
While empagliflozin has demonstrated a reduction in cardiovascular death and HF 
hospitalization risks, these analyses need to be replicated with other SGLT2 inhibitors before 
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it can be ascertained if this is a class effect or a drug-specific effect. In the near future, 
studies with canagliflozin and dapagliflozin will also report cardiovascular outcome results, 
shedding further light on this issue.88, 89  
 
FUTURE DIRECTION 
The EMPA-REG OUTCOME trial was designed to study high-risk T2DM patients. This trial 
was not designed to assess the benefits of empagliflozin in patients with HF. Only a distinct 
minority of these patients (~10%) had a history of HF. Secondary analyses of the HF sub-
group provides interesting hypotheses for potential benefits of this drug in HF; however the 
strength of evidence is not sufficient to recommend its use for the treatment of patients 
with HF and none of the HF guidelines currently recommend it for HF treatment. There have 
been examples in the past of cardiovascular drugs that have benefited patients with T2DM 
and CVD and were also shown to be of benefit in observational studies in HF. However, 
when dedicated adequately powered HF trials were done, no benefit was seen in improving 
HF outcomes.  
A full characterization of the HF population, including information regarding left 
ventricular ejection fraction was not performed in the EMPAREG OUTCOME trial, as this was 
not a HF study. None of the therapies shown to improve survival in patients with HF with 
reduced ejection fraction, such as angiotensin-converting enzyme inhibitors or beta-blockers 
or mineralocorticoid antagonists have been conclusively shown to improve outcomes in 
patients with HFpEF conclusively. Thus outcomes related to HF therapies should be tested in 
specific populations. Also, while EMPA-REG OUTCOME trial was performed in patients with 
T2DM, the pharmacodynamics effects of empagliflozin lends itself to potentially also benefit 
patients with HF who do not have DM. 
  Based on these reasons, it is imperative to study this drug in adequately designed and 
powered dedicated HF clinical trials. This is of particular importance considering the 
increasing prevalence of patients with both HF and T2DM concomitantly. While this 
possibility remains, further studies to better understand the pharmacodynamic effects of 
SGLT inhibitors in patients with HF, including those without DM, are warranted. Importantly, 
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larger outcomes trials are needed with these agents. These should of course also determine 
the safety of these agents including assessing rates of genital infection and ketosis risks, in 
particular.21 There are currently several phase III outcomes trials planned and just starting 
with empagliflozin and dapagliflozin. Empagliflozin will be studied in patients with HFpEF 
(EMPEROR-PRESERVED)90 and HFrEF (EMPEROR-REDUCED)91, including HF patients without 
T2DM with the composite primary endpoint of time to first event of adjudicated CV death or 
adjudicated HF. Dapagliflozin will be studied in patients with HFrEF (Dapa-HF)92 with the 
primary composite endpoint of CV death or hospitalization for HF or urgent HF visit as well 
as in patients with CKD (Dapa-CKD)93 Sotagliflozin and luseogliflozin, non-selective SGLT 1 
and 2 inhibitors, are also currently under development. (Table) 
 
 
Funding: None 
 
Conflicts of Interest: JB reports receiving research support from the National Institutes of Health, 
European Union, and Patient Centered Outcomes Research Institute; and serves as a consultant to 
Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cardiocell, CVRx Medtronic, Merck, Novartis, 
Relypsa, and ZS Pharma.  GF received committee member fees from Servie, Novartis, Bayer and 
research grants from European Union. SJP is a consultant for Boehringer Ingelheim. RAB provides 
consulting services and sits on the advisory committee for Medtronic, Beohringer Ingelheim and 
Pfizer/BMS. MB, JTG, AS, and HJW are employees of Boehringer Ingelheim. AKC is a consultant for 
Boehringer-Ingelheim and a contributor to Up-to-Date. JBG has received grants from Merck Sharp & 
Dohme, AstraZeneca, and GlaxoSmithKline; grants and personal fees from Merck Sharp & Dohme; 
other support from Boehringer-Ingelheim; and personal fees from Bioscientifica and The Endocrine 
Society. JLJ is supported in part by the Hutter Family Professorship in Cardiology, has received grant 
support from Siemens, Singulex, and Prevencio;,consulting income from Roche Diagnostics, Critical 
Diagnostics, Sphingotec, Phillips, and Novartis, and participates in clinical endpoint committees/data 
safety monitoring boards for Novartis, Amgen, Janssen, and Boehringer Ingelheim. CSPL supported 
by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received 
research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has 
consulted for Abbott Diagnostics, Bayer, Novartis, Takeda, Merck, Astra Zeneca, Janssen Research & 
Development, LLC, Menarini and Boehringer Ingelheim. GYHL serves as a consultant for 
 15 
Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim,  Microlife and Daiichi-
Sankyo. Speaker for Bayer, BM S/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and 
Daiichi-Sankyo. NM has served as a consultant to AstraZeneca, Amgen, BMS, Boehringer Ingelheim, 
Merck, Novo Nordisk, Roche and SanofiAventis. He has received grant support from Merck and 
Boehringer Ingelheim. In addition, he has served as a speaker for AstraZeneca, Amgen, Bayer, BMS, 
Boehringer Ingelheim, Lilly, Merck, Mitsubishi Tanabe Pharma Corporation, Novartis, Novo Nordisk, 
Pfizer, Roche and Sanofi-Aventis. JR has served on scientific advisory boards and received 
honorarium or consulting fees from Pfizer, Roche, Sanofi, Novo Nordisk, Eli Lilly, MannKind, 
GlaxoSmithKline, Takeda, Daiichi Sankyo, Johnson & Johnson, Novartis, Boehringer Ingelheim and 
Lexicon. He has also received grants/research support from Merck, Pfizer, Sanofi, Novo Nordisk, 
Roche, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Takeda, Novartis, AstraZeneca, 
Amylin, Johnson & Johnson, Daiichi Sankyo, MannKind, Lexicon and Boehringer Ingelheim. NS has 
consulted for Boehringer Ingelheim, Janssen, Merck, Amgen and Sanofi, had lecture fees from 
Boehringer Ingelheim and Amgen and grant funding from AstraZeneca. BMS reports research grants 
via the TIMI Study and Brigham and Women’s Hospital from AstraZeneca, Eisai, and Poxel. 
Consulting fees from AstraZeneca, Biogen Idec, Boehringer Ingelheim, Covance, Dr. Reddy’s 
Laboratory, Elsevier Practice Update Cardiology, GlaxoSmithKline, Lexicon, Merck, NovoNordisk, 
Sanofi, St. Jude's Medical, and equity in Health [at] Scale. SJS reports research support from the 
National Institutes of Health and the American Heart Association, and has served as an advisory 
board member for Actelion, Bayer, Merck, and Novartis. DWK serves as a consultant for Relypsa, 
GlaxoSmithKline, Abbvie, St. Luke’s Hospital, Kansas City, MO, Corvia Medicla, Merck, Bayer, and 
Medtronic, receives research support from NIH, Novartis, BMS, Astra-Zeneca, Bayer and has stock 
ownership in Relyspa and Gilead. S.V. reports research grant support and/or speaking honoraria from 
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, and Merck. FZ is a consultant, speaker, or a 
member of an advisory board for Actelion, Amgen, AstraZeneca, Bayer, Boehringer, Boston Scientific, 
CEVA, CVRx, Vifor-Fresenius, GE Healthcare, J&J, KBP BioSciences, Livanova, Novartis, NovoNordisk, 
Pfizer, Quantum Genomics, Relypsa, Resmed, Roche, Takeda; ZS Pharma and the founder of 
CardioRenal CVCT. SDA reports fees for consultancy and speaking from Boehringer Ingelheim, Bayer, 
Novartis, and Vifor International. Grant support for research from Abbott Vascular and Vifor 
International. CEH, SK, PAM, CRM, PP, and HT report no disclosures. 
 
  
 16 
REFERENCES 
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de 
Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, 
Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER, 
3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, 
Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, 
Virani SS, Woo D, Yeh RW and Turner MB. Heart Disease and Stroke Statistics-2016 Update: A 
Report From the American Heart Association. Circulation. 2016;133:e38-360. 
2. WHO. Global Report on Diabetes. 2016; 
http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1, Accessed 
December 20, 2016. 
3. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S and 
Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in 
patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 
2009;373:1765-72. 
4. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup 
PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, 
Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB and Danesh J. Diabetes mellitus, fasting 
glucose, and risk of cause-specific death. The New England journal of medicine. 2011;364:829-
41. 
5. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, 
Jr. and Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare 
professionals from the American Heart Association. Circulation. 1999;100:1134-46. 
6. Komajda M, Tavazzi L, Francq BG, Bohm M, Borer JS, Ford I and Swedberg K. Efficacy 
and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an 
analysis from the SHIFT trial. Eur J Heart Fail. 2015;17:1294-301. 
7. Fitchett DH, Udell JA and Inzucchi SE. Heart failure outcomes in clinical trials of 
glucose-lowering agents in patients with diabetes. Eur J Heart Fail. 2017;19:43-53. 
 17 
8. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito 
JM, Vasan RS, Benjamin EJ and Levy D. Lifetime risk for developing congestive heart failure: 
the Framingham Heart Study. Circulation. 2002;106:3068-72. 
9. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC and Coats 
AJ. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. 
J Am Coll Cardiol. 1997;30:527-32. 
10. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL and Redfield MM. Trends in 
prevalence and outcome of heart failure with preserved ejection fraction. The New England 
journal of medicine. 2006;355:251-9. 
11. Zhou L, Deng W, Zhou L, Fang P, He D, Zhang W, Liu K and Hu R. Prevalence, 
incidence and risk factors of chronic heart failure in the type 2 diabetic population: 
systematic review. Curr Diabetes Rev. 2009;5:171-84. 
12. Dinesh Shah A, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale 
CP, Deanfield J, Smeeth L, Timmis A and Hemingway H. Type 2 diabetes and incidence of a 
wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet. 2015;385 
Suppl 1:S86. 
13. McMurray JJ, Gerstein HC, Holman RR and Pfeffer MA. Heart failure: a cardiovascular 
outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843-51. 
14. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME and Scirica BM. Glucose-
lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 
2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 
2015;3:356-66. 
15. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, 
Komajda M and McMurray JJ. Rosiglitazone evaluated for cardiovascular outcomes in oral 
agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-
label trial. Lancet. 2009;373:2125-35. 
16. Lincoff AM, Wolski K, Nicholls SJ and Nissen SE. Pioglitazone and risk of 
cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of 
randomized trials. Jama. 2007;298:1180-8. 
 18 
17. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-
Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, 
Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH and van der Meer P. 
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The 
Task Force for the diagnosis and treatment of acute and chronic heart failure of the 
European Society of Cardiology (ESC)Developed with the special contribution of the Heart 
Failure Association (HFA) of the ESC. European heart journal. 2016;37:2129-200. 
18. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, 
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, 
McGuire DK, Ray KK, Leiter LA and Raz I. Saxagliptin and cardiovascular outcomes in 
patients with type 2 diabetes mellitus. The New England journal of medicine. 2013;369:1317-26. 
19. McAlister FA, Eurich DT, Majumdar SR and Johnson JA. The risk of heart failure in 
patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 
2008;10:703-8. 
20. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, 
Johansen OE and Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the 
sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis 
Res. 2013;10:289-301. 
21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins 
T, Johansen OE and Woerle HJ. Empagliflozin, cardiovascular outcomes, and mortality in 
type 2 diabetes. The New England journal of medicine. 2015;373:2117-28. 
22. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle 
HJ, Broedl UC and Inzucchi SE. Heart failure outcomes with empagliflozin in patients with 
type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur 
Heart J. 2016;37:1526-34. 
23. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, 
Genuth S, Ismail-Beigi F and Grimm RH. Effects of intensive glucose lowering in type 2 
diabetes. The New England journal of medicine. 2008;358:2545-59. 
 19 
24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-
converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama. 2002;288:2981-
97. 
25. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen 
H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S and 
Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint 
reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 
2002;359:995-1003. 
26. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, 
Macdonald GJ, Marley JE, Morgan TO and West MJ. A comparison of outcomes with 
angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. The 
New England journal of medicine. 2003;348:583-92. 
27. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, 
McInnes GT, Mitchell L, Plat F, Schork A, Smith B and Zanchetti A. Outcomes in hypertensive 
patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: 
the VALUE randomised trial. Lancet. 2004;363:2022-31. 
28. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, 
Granger CB, Michelson EL, Pocock S and Pfeffer MA. Effect of candesartan on cause-specific 
mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction 
in Mortality and morbidity (CHARM) program. Circulation. 2004;110:2180-3. 
29. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, 
Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie 
BM and Carson PE. Mode of death in patients with heart failure and a preserved ejection 
fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study 
(I-Preserve) trial. Circulation. 2010;121:1393-405. 
30. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, 
Adams KF, Jr. and Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic 
heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114:397-403. 
 20 
31. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L and Taylor J. The 
perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 
2006;27:2338-45. 
32. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, 
Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield 
JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S and McKinlay SM. 
Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of 
Medicine. 2014;370:1383-1392. 
33. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, 
Pfeffer MA and Swedberg K. Effects of candesartan in patients with chronic heart failure and 
reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme 
inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-6. 
34. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, 
Yusuf S and Pfeffer MA. Effects of candesartan in patients with chronic heart failure and 
reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: 
the CHARM-Added trial. Lancet. 2003;362:767-71. 
35. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi 
VC, Solomon SD, Swedberg K and Zile MR. Angiotensin–Neprilysin Inhibition versus Enalapril 
in Heart Failure. New England Journal of Medicine. 2014;371:993-1004. 
36. Fang JC. Heart Failure With Preserved Ejection Fraction: A Kidney Disorder? 
Circulation. 2016;134:435-7. 
37. Fitchett D, Inzucchi SE, Wanner C, Mattheus M, T. GJ, Woerle HJ and Zinman B. 
Reduction in hospitalisation for heart failure with empagliflozin is consistent across 
categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME 
trial. Poster presented at: ESC-HF 2017; January 2017. 
38. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, 
Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J and Vilsboll T. 
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New 
England journal of medicine. 2016;375:1834-1844. 
 21 
39. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen 
SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM and 
Buse JB. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England 
journal of medicine. 2016;375:311-22. 
40. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, 
Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E and 
Cappola TP. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart 
Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Jama. 2016;316:500-8. 
41. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, Nilsson B, 
Moller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg 
A, Wiggers H and Tarnow L. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left 
ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-
a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69-
77. 
42. Heerspink HJ, Perkins BA, Fitchett DH, Husain M and Cherney DZ. Sodium Glucose 
Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney 
Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134:752-72. 
43. Nauck MA. Update on developments with SGLT2 inhibitors in the management of 
type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-80. 
44. Sattar N, McLaren J, Kristensen SL, Preiss D and McMurray JJ. SGLT2 Inhibition and 
cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely 
mechanisms? Diabetologia. 2016;59:1333-9. 
45. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW and White WB. Effects 
of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and 
meta-analysis. J Am Soc Hypertens. 2014;8:262-75.e9. 
46. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, 
von Eynatten M and Broedl UC. The effect of empagliflozin on arterial stiffness and heart 
rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 
2014;13:28. 
 22 
47. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle 
HJ, Broedl UC and Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed 
pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90-100. 
48. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle 
HJ, Johansen OE, Broedl UC and von Eynatten M. Renal hemodynamic effect of sodium-
glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 
2014;129:587-97. 
49. Rajasekeran H, Lytvyn Y and Cherney DZ. Sodium-glucose cotransporter 2 inhibition 
and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of 
natriuresis. Kidney Int. 2016;89:524-6. 
50. Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ and 
Broedl UC. Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in 
Patients With Type 2 Diabetes. Clin Ther. 2016;38:2265-2276. 
51. Liu T, Takimoto E, Dimaano VL, DeMazumder D, Kettlewell S, Smith G, Sidor A, 
Abraham TP and O'Rourke B. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden 
death in a Guinea pig model of heart failure. Circ Res. 2014;115:44-54. 
52. Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG 
OUTCOME trial: Comparison with classic diuretics. Diabetes & metabolism. 2016;42:224-33. 
53. Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC and Malnic G. Functional role of 
glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated 
transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc 
Nephrol. 2014;25:2028-39. 
54. Layton AT, Vallon V and Edwards A. Modeling oxygen consumption in the proximal 
tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Renal Physiol. 2015;308:F1343-57. 
55. Inoue BH, dos Santos L, Pessoa TD, Antonio EL, Pacheco BP, Savignano FA, Carraro-
Lacroix LR, Tucci PJ, Malnic G and Girardi AC. Increased NHE3 abundance and transport 
activity in renal proximal tubule of rats with heart failure. Am J Physiol Regul Integr Comp 
Physiol. 2012;302:R166-74. 
 23 
56. Gallo LA, Wright EM and Vallon V. Probing SGLT2 as a therapeutic target for diabetes: 
basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78-89. 
57. Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WH and Mullens W. 
The kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, 
the bad and the ugly?'. Eur J Heart Fail. 2014;16:133-42. 
58. Verbrugge FH, Vangoitsenhoven R, Mullens W, Van der Schueren B, Mathieu C and 
Tang WHW. SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure 
in Diabetes? Current Cardiovascular Risk Reports. 2015;9:38. 
59. Bautista R, Manning R, Martinez F, Avila-Casado Mdel C, Soto V, Medina A and 
Escalante B. Angiotensin II-dependent increased expression of Na+-glucose cotransporter in 
hypertension. Am J Physiol Renal Physiol. 2004;286:F127-33. 
60. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni 
M, Matthews DR and Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 
diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-74. 
61. Riggs K, Ali H, Taegtmeyer H and Gutierrez AD. The Use of SGLT-2 Inhibitors in Type 2 
Diabetes and Heart Failure. Metab Syndr Relat Disord. 2015;13:292-7. 
62. Rosengren A, Aberg M, Robertson J, Waern M, Schaufelberger M, Kuhn G, Aberg D, 
Schioler L and Toren K. Body weight in adolescence and long-term risk of early heart failure 
in adulthood among men in Sweden. Eur Heart J. 2016; ehw221. doi: 10.1093/eurheartj/ehw221. 
63. The Look AHEAD Research Group. Cardiovascular Effects of Intensive Lifestyle 
Intervention in Type 2 Diabetes. New England Journal of Medicine. 2013;369:145-154. 
64. Heerspink HJ and de Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud. 
2011;8:392-402. 
65. Hamano K, Nitta A, Ohtake T and Kobayashi S. Associations of renal vascular 
resistance with albuminuria and other macroangiopathy in type 2 diabetic patients. Diabetes 
care. 2008;31:1853-7. 
66. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen 
OE, Woerle HJ, Broedl UC and Zinman B. Empagliflozin and Progression of Kidney Disease in 
Type 2 Diabetes. The New England journal of medicine. 2016;375:323-34. 
 24 
67. Lytvyn Y, Perkins BA and Cherney DZ. Uric acid as a biomarker and a therapeutic 
target in diabetes. Can J Diabetes. 2015;39:239-46. 
68. Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, Sanders PW, Pitt B, 
Anker SD and Ahmed A. Hyperuricaemia, chronic kidney disease, and outcomes in heart 
failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011;32:712-20. 
69. Lytvyn Y, Skrtic M, Yang GK, Yip PM, Perkins BA and Cherney DZ. Glycosuria-mediated 
urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J 
Physiol Renal Physiol. 2015;308:F77-83. 
70. Oelze M, Kroller-Schon S, Welschof P, Jansen T, Hausding M, Mikhed Y, Stamm P, 
Mader M, Zinssius E, Agdauletova S, Gottschlich A, Steven S, Schulz E, Bottari SP, Mayoux E, 
Munzel T and Daiber A. The sodium-glucose co-transporter 2 inhibitor empagliflozin 
improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by 
interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9:e112394. 
71. Zinman B, Lachin JM and Inzucchi SE. Empagliflozin, Cardiovascular Outcomes, and 
Mortality in Type 2 Diabetes. The New England journal of medicine. 2016;374:1094. 
72. Inzucchi S. SGLT2 inhibition and cardiovascular outcomes. EASD Virtual Meeting. 2016. 
http://www.easdvirtualmeeting.org/resources/sglt2-inhibition-and-cardiovascular-outcomes; 
Accessed May 23, 2017. 
73. Sano M, Takei M, Shiraishi Y and Suzuki Y. Increased Hematocrit During Sodium-
Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function 
in Diabetic Kidneys. J Clin Med Res. 2016;8:844-847. 
74. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B and List J. Dapagliflozin a glucose-
regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, obesity & 
metabolism. 2013;15:853-62. 
75. Chang YK, Choi H, Jeong JY, Na KR, Lee KW, Lim BJ and Choi DE. Dapagliflozin, SGLT2 
Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury. PloS one. 2016;11:e0158810. 
76. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, 
Imamura M, Li Q and Tomiyama H. Effects of SGLT2 selective inhibitor ipragliflozin on 
 25 
hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity 
in type 2 diabetic mice. Eur J Pharmacol. 2013;715:246-55. 
77. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC and Johansen OE. 
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular 
resistance in patients with type 2 diabetes. Diabetes, obesity & metabolism. 2015;17:1180-93. 
78. Shah SJ and Wasserstrom JA. Increased arterial wave reflection magnitude: a novel 
form of stage B heart failure? Journal of the American College of Cardiology. 2012;60:2178-81. 
79. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC and Woerle HJ. 
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. 
J Clin Invest. 2014;124:499-508. 
80. Jones BJ, Tan T and Bloom SR. Minireview: Glucagon in stress and energy 
homeostasis. Endocrinology. 2012;153:1049-54. 
81. Mery PF, Brechler V, Pavoine C, Pecker F and Fischmeister R. Glucagon stimulates the 
cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. 
Nature. 1990;345:158-61. 
82. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR 
and Muscelli E. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose 
Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. 
Diabetes. 2016;65:1190-5. 
83. Mudaliar S, Alloju S and Henry RR. Can a Shift in Fuel Energetics Explain the Beneficial 
Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes 
Care. 2016;39:1115-22. 
84. Ferrannini E, Mark M and Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: 
A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016;39:1108-14. 
85. Lopaschuk GD and Verma S. Empagliflozin's Fuel Hypothesis: Not so Soon. Cell Metab. 
2016;24:200-2. 
86. Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD and 
Connelly KA. Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in 
 26 
Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Diabetes 
care. 2016;39:e212-e213. 
87. Shi X, Verma S, Yun J, Brand-Arzamendi K, Singh KK, Liu X, Garg A, Quan A and Wen 
XY. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues 
to the EMPA-REG OUTCOME trial? Molecular and cellular biochemistry. 2017. 
doi:10.1007/s11010-017-3018-9. 
88. Neal B, Perkovic V, Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, 
Jiang J and Vercruysse F. Rationale, design, and baseline characteristics of the Canagliflozin 
cardiovascular assessment study (CANVAS)–a randomized placebo-controlled trial. Am Heart 
J. 2013;166:217-223. 
89. National Institute of Health. Multicenter Trial to Evaluate the Effect of Dapagliflozin 
on the Incidence of Cardiovascular Events (DECLARE-TIMI58). 2017, 
https://clinicaltrials.gov/ct2/show/NCT01730534?term=Multicenter+Trial+to+Evaluate+the+Ef
fect+of+Dapagliflozin+on+the+Incidence+of+Cardiovascular+Events&rank=1 , Accessed 
March 29, 2017. 
90. National Institute of Health. EMPagliflozin outcomE tRial in Patients With chrOnic 
heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). 2017; 
https://clinicaltrials.gov/ct2/show/NCT03057951?term=empagliflozin+phase+III&rank=4, 
Accessed March 9, 2017. 
91. National Institute of Health. EMPagliflozin outcomE tRial in Patients With chrOnic 
heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). 2017; 
https://clinicaltrials.gov/ct2/show/NCT03057951?term=empagliflozin+phase+III&rank=4, 
Accessed March 9, 2017. 
92. National Institute of Health. Study to Evaluate the Effect of Dapagliflozin on the 
Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart 
Failure (Dapa-HF). 2017; 
https://clinicaltrials.gov/ct2/show/NCT03036124?term=dapagliflozin+heart+failure+phase+3&
rank=1, Accessed March 9, 2017. 
 27 
93. National Institute of Health. A Study to Evaluate the Effect of Dapagliflozin on Renal 
Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD). 
2017; 
https://clinicaltrials.gov/ct2/show/NCT03036124?term=dapagliflozin+heart+failure+phase+3&
rank=1, Accessed March 9, 2017. 
 
 
 28 
LEGENDS 
 
Figure 1. Comparison of mortality and heart failure hospitalization rates in the EMPAREG 
OUTCOME versus other trials 
Comparison of overall mortality (A) and heart failure hospitalization (B) rates between 
hypertension, heart failure preserved ejection fraction (HFpEF) heart failure reduced 
ejection fraction (HFrEF) trials with EMPAREG OUTCOME trial. Participants with heart failure 
in the EMPAREG OUTCOME trials had comparable risk to that seen in patients with HFpEF.  
 
ACCORD, Action to Control Cardiovascular Risk in Diabetes; LIFE, Losartan Intervention for Endpoint reduction 
in hypertension; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; VALUE, 
Valsartan Antihypertensive Long-term Use Evaluation; ANBP-2, second Australian National, Losartan 
Intervention for Endpoint reduction in hypertension; CHARM-Preserved, CHARM-Added, CHARM-Alternative, 
Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; I-PRESERVE, Irbesartan in 
Heart Failure with Preserved Systolic Function Trial; TOPCAT, Treatment of Preserved Cardiac Function Heart 
Failure with an Aldosterone Antagonist; PEP-CHF, Perindopril in elderly people with chronic heart failure; DIG-
PEF, Digitalis Investigation Group Congestive Heart Failure; PARADIGM-HF, Prospective comparison of ARNI 
with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure. 
 
Figure 2. Mechanism of Action of SGLT-2 inhibitors 
The sodium glucose cotransporter (SGLT)-2 inhibitor empagliflozin works primarily at the 
proximal convoluted tubule of the nephron inhibiting the reabsorption of glucose and 
sodium.  
 
Figure 3. Potential Pathways Linking Empagliflozin with Heart Failure Outcome 
Improvement 
CV, cardiovascular; HF, heart failure; HHF, hospitalization for heart failure; REG, removal of excess 
glucose; UNa, urinary sodium 
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Table. Ongoing Trials with SGLT-2 Inhibitors 
 
Drug Cohort Primary Endpoint 
Canagliflozin* 
 
 
Chronic HF Change from baseline aerobic 
exercise capacity at 12 weeks 
Change from baseline ventilator 
efficiency at 12 weeks 
Dapagliflozin* 
 
Chronic HF 
 
 
CKD 
Time to first occurrence of CV death 
or hospitalization for HF or urgent HF 
visit 
Time to first occurrence of ≥50% 
sustained decline in eGFR or reaching 
ESRD or CV death or renal death 
Empagliflozin* 
 
HFpEF 
HFrEF 
Time to first adjudicated CV death or 
adjudicated hospitalization for HF 
Luseogliflozin 
 
HFpEF Change in BNP at 12 weeks 
Ertugliflozin n/a n/a 
Sotagliflozin 
 
n/a n/a 
* Currently approved by Food and Drug Administration and European Medicines Agency 
BNP, b-type natriuretic peptide; CKD, chronic kidney disease; CV, cardiovascular; eGFR, 
estimated glomerular filtration rate; ESRD, end stage renal disease; HF, heart failure; HFpEF, 
heart failure preserved ejection fraction; HFrEF, heart failure reduced ejection fraction 
 
 
 
 
